Drug Profile
VX 135
Alternative Names: ALS-002200; ALS-2200; VX-135Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Alios BioPharma
- Developer Alios BioPharma; Bristol-Myers Squibb; Vertex Pharmaceuticals
- Class Antivirals; Uracil nucleotides
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 01 May 2014 Vertex Pharmaceuticals and Bristol-Myers Squibb complete a phase II trial in Hepatitis C (Combination therapy, Treatment-naive) in New Zealand (NCT01842451)
- 01 May 2014 Discontinued - Phase-I for Hepatitis C (Treatment-naive) in France and Romania (PO)
- 01 May 2014 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in USA, Moldova and New Zealand (PO)